These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 10233923)

  • 1. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.
    VanCott TC; Mascola JR; Loomis-Price LD; Sinangil F; Zitomersky N; McNeil J; Robb ML; Birx DL; Barnett S
    J Virol; 1999 Jun; 73(6):4640-50. PubMed ID: 10233923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
    Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
    J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.
    Haigwood NL; Nara PL; Brooks E; Van Nest GA; Ott G; Higgins KW; Dunlop N; Scandella CJ; Eichberg JW; Steimer KS
    J Virol; 1992 Jan; 66(1):172-82. PubMed ID: 1727480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
    VanCott TC; Mascola JR; Kaminski RW; Kalyanaraman V; Hallberg PL; Burnett PR; Ulrich JT; Rechtman DJ; Birx DL
    J Virol; 1997 Jun; 71(6):4319-30. PubMed ID: 9151820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
    Verrier F; Burda S; Belshe R; Duliege AM; Excler JL; Klein M; Zolla-Pazner S
    J Virol; 2000 Nov; 74(21):10025-33. PubMed ID: 11024131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120.
    Schønning K; Bolmstedt A; Novotny J; Lund OS; Olofsson S; Hansen JE
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1451-6. PubMed ID: 9824323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.
    O'Hagan DT; Ugozzoli M; Barackman J; Singh M; Kazzaz J; Higgins K; Vancott TC; Ott G
    Vaccine; 2000 Mar; 18(17):1793-801. PubMed ID: 10699327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals.
    Beddows S; Lister S; Cheingsong R; Bruck C; Weber J
    J Virol; 1999 Feb; 73(2):1740-5. PubMed ID: 9882391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
    Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
    Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates.
    Lee SA; Orque R; Escarpe PA; Peterson ML; Good JW; Zaharias EM; Berman PW; Sheppard HW; Shibata R
    Vaccine; 2001 Nov; 20(3-4):563-76. PubMed ID: 11672923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
    Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; Weber J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):315-20. PubMed ID: 9833739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
    J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits.
    Qin Y; Shi H; Banerjee S; Agrawal A; Banasik M; Cho MW
    Retrovirology; 2014 Dec; 11():125. PubMed ID: 25527085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.